Condition: Alopecia Areata · Sponsor: Pfizer
Alopecia areata (AA) is a chronic relapsing autoimmune disease characterized by nonscarring hair loss affecting children, adolescents, and adults across all ages, races, and genders. AA primarily affects the scalp; however, it also can affect nails, eyelashes, eyebrows, and other hair follicles on the patient's body. The 3 main types of AA are: * Patchy alopecia (PA), as seen in 90% of clinical diagnoses * Alopecia totalis (AT), that affects all scalp hair * Alopecia universalis (AU), involving all scalp, face, and body hair Dermatologist preferences for utility and order of skin-directed therapies to treat AA vary widely, with treatment choices based on various factors such as patients' age, disease duration and severity (Meah et al., 2020). Ritlecitinib is a bioavailable small molecule that irreversibly binds to Janus kinase-3 (JAK3) and Tyrosine kinase Expressed in the hepatocellular Carcinoma kinase family (TEC). Ritlecitinib 50 mg once daily was approved by the FDA 23 June 2023 and EMA 20 July 2023 for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older. In Japan, ritlecitinib was approved on 26 June 2023 for the treatment of alopecia areata (limited to intractable cases involving widespread hair loss). Additional countries have since approved ritlecitinib. Those approvals are based on the results of the ritlecitinib pivotal phase 2b/3 study (ALLEGRO 2b/3) which examined efficacy and safety of ritlecitinib in AA patients globally…
This description comes directly from the study's public registry record.
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| C2 Research Center | Montgomery, Alabama, United States | Recruiting |
| CENTER FOR DERMATOLOGY CLINICAL RESEARCH, Inc | Fremont, California, United States | Recruiting |
| Rao Dermatology | Fresno, California, United States | Active Not Recruiting |
| Rao Dermatology | Fresno, California, United States | Recruiting |
| Cura Clinical Research | Oxnard, California, United States | Recruiting |
| Stanford | Redwood City, California, United States | Not Yet Recruiting |
| Southern California Clinical Research | Santa Ana, California, United States | Recruiting |
| Dermatology of Boca | Boca Raton, Florida, United States | Recruiting |
| Pediatric Skin Research,LLC | Coral Gables, Florida, United States | Recruiting |
| Suncoast Skin Solutions | Jacksonville, Florida, United States | Recruiting |
| University of Miami | Miami, Florida, United States | Recruiting |
+ 69 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06531109